Compare UMC & ONC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UMC | ONC |
|---|---|---|
| Founded | 1980 | 2010 |
| Country | Taiwan | Switzerland |
| Employees | N/A | 12000 |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.3B | 31.4B |
| IPO Year | 1997 | N/A |
| Metric | UMC | ONC |
|---|---|---|
| Price | $18.23 | $309.12 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $385.10 |
| AVG Volume (30 Days) | ★ 13.7M | 206.8K |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.92% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $11.22 | $723.76 |
| Revenue Next Year | $10.15 | $15.04 |
| P/E Ratio | ★ $18.95 | $614.06 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.56 | $235.35 |
| 52 Week High | $18.45 | $385.22 |
| Indicator | UMC | ONC |
|---|---|---|
| Relative Strength Index (RSI) | 81.76 | 53.07 |
| Support Level | $7.03 | $302.26 |
| Resistance Level | N/A | $325.40 |
| Average True Range (ATR) | 0.69 | 8.51 |
| MACD | 0.16 | 0.22 |
| Stochastic Oscillator | 94.93 | 59.18 |
Founded in 1980, United Microelectronics is the world's third-largest dedicated chip foundry, with 5% market share in 2024 after TSMC and SMIC. UMC's headquarters are in Hsinchu, Taiwan, and it operates 12 fabs in Taiwan, Mainland China, Japan and Singapore, with additional sales offices in Europe, the US, and South Korea. UMC features a diverse customer base that includes Texas Instruments, MediaTek, Intel, Broadcom, Novatek, and Realtek, supplying a wide range of products applied in communications, display, memory, automotive and more. UMC employs about 19,000 people as of February 2025.
BeOne Medicines Ltd is a holding company. Through its subsidiaries, it operates as an oncology-focused biopharmaceutical company engaged in the discovery and development of treatments for cancer. Its portfolio includes BRUKINSA (a Bruton's tyrosine kinase (BTK) inhibitor), sonrotoclax (a B-cell lymphoma 2 (BCL2) inhibitor, and a BTK chimeric degradation activation compound (BTK-CDAC). The company develops and commercializes wholly owned therapeutic assets targeting multiple mechanisms of action in oncology. The company operates in one segment: pharmaceutical products. It generates the majority of its revenue from the sale of its biopharmaceutical products.